Show simple item record

dc.contributor.authorLampis, A
dc.contributor.authorHahne, JC
dc.contributor.authorHedayat, S
dc.contributor.authorValeri, N
dc.date.accessioned2020-09-30T14:25:35Z
dc.date.issued2020-10-01
dc.identifier.citationCurrent opinion in pharmacology, 2020, 54 pp. 44 - 50
dc.identifier.issn1471-4892
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4115
dc.identifier.eissn1471-4973
dc.identifier.doi10.1016/j.coph.2020.08.004
dc.description.abstractMicroRNAs are small RNA transcripts involved in fine-tuning of several cellular mechanisms and pathways crucial for maintaining cells' homeostasis like apoptosis, differentiation, inflammation and cell-cycle regulation. They act by regulation of gene expression at post-transcriptional level through fine-tuning of target proteins expression. Expression of microRNAs is cell-type specific and since their discovery they have been proven to be deregulated in various disorders including cancer. Several lines of evidence are emerging that link microRNAs to drug resistance mechanisms in tumours given their important role in modulating oncogenic and tumour suppressive mechanisms. This review will focus on latest knowledge of the roles and mechanisms of microRNAs as mediators to drug resistance and the implications for future therapies.
dc.formatPrint-Electronic
dc.format.extent44 - 50
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.titleMicroRNAs as mediators of drug resistance mechanisms.
dc.typeJournal Article
dcterms.dateAccepted2020-08-05
rioxxterms.versionofrecord10.1016/j.coph.2020.08.004
rioxxterms.licenseref.startdate2020-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCurrent opinion in pharmacology
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.publication-statusPublished
pubs.volume54
pubs.embargo.terms12 months
icr.researchteamEvolutionary Genomics & Modelling
icr.researchteamFunctional Genomics
icr.researchteamGastrointestinal Cancer Biology and Genomics
dc.contributor.icrauthorLampis, Andrea
dc.contributor.icrauthorHahne, Jens
dc.contributor.icrauthorHedayat-Husseyin, Somaieh
dc.contributor.icrauthorValeri, Nicola


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record